LivaNova (NASDAQ:LIVN) Given New $55.00 Price Target at The Goldman Sachs Group

LivaNova (NASDAQ:LIVN) had its target price lowered by equities researchers at The Goldman Sachs Group from $64.00 to $55.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target indicates a potential upside of 32.42% from the company’s previous close.

LIVN has been the subject of several other reports. Needham & Company LLC reduced their price objective on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Mizuho dropped their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Finally, Stifel Nicolaus decreased their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $62.20.

LivaNova Stock Down 0.2 %

LIVN traded down $0.09 during trading on Monday, hitting $41.54. 22,248 shares of the company’s stock traded hands, compared to its average volume of 568,144. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of 98.65 and a beta of 1.00. The company’s 50 day simple moving average is $47.40 and its two-hundred day simple moving average is $49.56. LivaNova has a 12-month low of $40.37 and a 12-month high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.27% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. raised its stake in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the period. Sterling Capital Management LLC increased its stake in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after purchasing an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division raised its position in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after purchasing an additional 720 shares during the period. Captrust Financial Advisors purchased a new position in shares of LivaNova during the 3rd quarter valued at $217,000. Finally, Sanctuary Advisors LLC bought a new position in LivaNova in the 3rd quarter worth $219,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.